Publications

TALETRECTINIB

June, 2024

Journal of Clinical Oncology

Efficacy and Safety of Taletrectinib in Chinese Patients with ROS1+ Non-Small Cell Lung Cancer: The Phase II TRUST-I Study

DOI: 10.1200/JCO.24.00731

June, 2024

ASCO 2024 Oral Presentation

Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1+ Non-Small Cell Lung Cancer: The Phase 2 TRUST-I Study

October, 2023

ESMO 2023 Poster Presentation

Efficacy and Safety of Taletrectinib in Patients with ROS1+ NSCLC: Interim Analysis of Global TRUST-II Study (pdf)

March, 2023

ELCC 2023 Mini Oral Presentation

Updated Efficacy and Safety of Taletrectinib in Patients with ROS1+ Non–Small Cell Lung Cancer (pdf)

March, 2023

Future Oncology

TRUST-II: a Global Phase II Study of Taletrectinib in ROS1-Positive Non-Small-Cell Lung Cancer and Other Solid Tumors

PMID: 36877099

June, 2022

ASCO 2022 Poster Presentation

TRUST: The Efficacy and Safety of Taletrectinib in TKI-Naïve or Crizotinib-Pretreated ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) Patients (pdf)

April, 2022

ELCC 2022 Poster Presentation

A Global Phase 2 Study of Taletrectinib, a Next Generation of ROS1 TKI, in ROS1 Positive Lung Cancer and Other Solid Tumors (TRUST II) (pdf)

September, 2021

CSCO 2021 Oral Presentation

A Phase II Clinical Study to Investigate Taletrectinib (AB-106) in Treating Patients with ROS1 Fusion Positive Non-Small Cell Lung Cancer (TRUST Phase II study) (pdf)

June, 2021

ASCO 2021 Poster Presentation

Preliminary Results from TRUST: A Phase II Clinical Study to Investigate Taletrectinib in Treating Patients with ROS1 Fusion Positive Non-small Cell Lung Cancer (NSCLC) (pdf)

October, 2020

JTO Clinical and Research Reports

Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies

PMID: 34589973 PMCID: PMC8474193
DOI: 10.1016/j.jtocrr.2020.100108

September, 2020

Clinical Cancer Research

U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors

PMID: 32591465
DOI: 10.1158/1078-0432.CCR-20-1630

August, 2019

Nature Communications

The New-Generation Selective ROS1/NTRK Inhibitor DS-6051b Overcomes Crizotinib Resistant ROS1-G2032R Mutation in Preclinical Models

PMID: 31399568 PMCID: PMC6688997
DOI: 10.1038/s41467-019-11496-z

May, 2018

Oncotarget

Safety and Pharmacokinetics of DS-6051b in Japanese Patients with Non-small Cell Lung Cancer Harboring ROS1 Fusions: a Phase I Study

PMID: 29805770 PMCID: PMC5955103
DOI: 10.18632/oncotarget.25263

SAFUSIDENIB

June, 2022

Neuro-Oncology

The first-in-human phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas

February, 2020

Molecular Cancer Therapeutics

A Potent Blood–Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model

August, 2019

Oncogene

Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma

AB-329

August, 2019

Oncotarget

DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model

PUBLICATIONS

TALETRECTINIB

Efficacy and Safety of Taletrectinib in Chinese Patients with ROS1+ Non-Small Cell Lung Cancer: The Phase II TRUST-I Study

Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1+ Non-Small Cell Lung Cancer: The Phase 2 TRUST-I Study

Efficacy and Safety of Taletrectinib in Patients with ROS1+ NSCLC: Interim Analysis of Global TRUST-II Study (pdf)

Updated Efficacy and Safety of Taletrectinib in Patients with ROS1+ Non–Small Cell Lung Cancer (pdf)

TRUST-II: a Global Phase II Study of Taletrectinib in ROS1-Positive Non-Small-Cell Lung Cancer and Other Solid Tumors

TRUST: The Efficacy and Safety of Taletrectinib in TKI-Naïve or Crizotinib-Pretreated ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) Patients (pdf)

A Global Phase 2 Study of Taletrectinib, a Next Generation of ROS1 TKI, in ROS1 Positive Lung Cancer and Other Solid Tumors (TRUST II) (pdf)

A Phase II Clinical Study to Investigate Taletrectinib (AB-106) in Treating Patients with ROS1 Fusion Positive Non-Small Cell Lung Cancer (TRUST Phase II study) (pdf)

Preliminary Results from TRUST: A Phase II Clinical Study to Investigate Taletrectinib in Treating Patients with ROS1 Fusion Positive Non-small Cell Lung Cancer (NSCLC) (pdf)

Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies

U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors

The New-Generation Selective ROS1/NTRK Inhibitor DS-6051b Overcomes Crizotinib Resistant ROS1-G2032R Mutation in Preclinical Models

Safety and Pharmacokinetics of DS-6051b in Japanese Patients with Non-small Cell Lung Cancer Harboring ROS1 Fusions: a Phase I Study

SAFUSIDENIB

The first-in-human phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas

A Potent Blood–Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model

Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma

AB-329

DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model

About us

General Inquiries

Media or Investor Inquiries